Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.23 -0.45%
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.00, $0.03 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $21.4 million versus the consensus estimate of $11.97 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Update
- Akari Therapeutics to present ADC platform at five September conferences
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
